BioNTech SE - ADR

-6.13 (-3.82%)
Products, Strategic Combinations

BioNTech And Crescendo Biologics Announce Collaboration To Develop Multi-Specific Immunotherapies

Published: 01/10/2022 13:12 GMT
BioNTech SE - ADR (BNTX) - Biontech and Crescendo Biologics Announce Global Collaboration to Develop Multi-specific Precision Immunotherapies.
Biontech Will Hold Exclusive Worldwide Development and Commercialization Rights to All Immunotherapies Arising From Collaboration.
Crescendo Will Receive $40 Million Upfront, Including a Cash Payment and an Equity Investment From Biontech, As Well As Research Funding.
Crescendo Will Be Eligible to Receive Development, Regulatory and Commercial Milestone Payments Up to a Total of More Than $750 Million, Plus Tiered Royalties on Global Net Sales.